In patients with pancreatic adenocarcinoma, blockade of CCR2 prevented the accumulation of TAM in tumour sites but led to a compensatory CXCR2+ TANs influx, which possibly limited the intended treatment efficacy.157. The gene discussed is CCR2; the disease is neoplasm.